Evidence map›Paper›PMID 26374100›Full record

ArticleBMC research notes2015

Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania.

Phillipo L Chalya, Fidelis Mbunda, Peter F Rambau, Hyasinta Jaka, Nestory Masalu, Mariam Mirambo, Martha F Mushi, Samuel E Kalluvya

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Lack of CD8Oncotarget · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Phillipo L ChalyaDepartment of Surgery, Bugando Medical Centre, Mwanza, Tanzania. drphillipoleo@yahoo.com.
Fidelis MbundaDepartment of Surgery, Bugando Medical Centre, Mwanza, Tanzania.
Peter F RambauDepartment of Pathology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania.
Hyasinta JakaDepartment of Internal Medicine, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania.
Nestory MasaluDepartment of Oncology, Bugando Medical Centre, Mwanza, Tanzania.
Mariam MiramboDepartment of Microbiology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania.
Martha F MushiDepartment of Microbiology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania.
Samuel E KalluvyaDepartment of Internal Medicine, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania.
Catholic University of Health and Allied Sciences · TZBugando Medical Centre · TZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKaposi's Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania. Little is known about Kaposi's sarcoma in our setting as there is paucity of recent published data regarding this condition. This study describes the clinicopathological pattern and treatment outcome of Kaposi's sarcoma at Bugando Medical Centre, a tertiary care hospital in northwestern Tanzania.

methodsThis was a prospective study of histologically confirmed Kaposi's sarcoma that was conducted at Bugando Medical Center between July 2004 and June 2014.

resultsA total of 248 patients (M:F = 1.4:1) representing 2.4% of all malignancies during the study period were enrolled into the study. The median age at presentation was 36 years. Females were younger than males (p = 0.04). Out of 248 patients, 122 (49.2%) were HIV positive. Of these, 46 (37.7%) were males and 76 (62.3%) females. AIDS-related Kaposi's sarcoma were younger than HIV negative Kaposi's sarcoma patients (p = 0.011). Median duration of symptoms was 6 months. Kaposi's sarcoma was the AIDS defining disease in 82 (67.2%) patients while in the remaining 40 (32.8%) it was diagnosed between 1 and 14 months after the initial diagnosis of AIDS. The lower limb was most frequently involved site in 28.9% of patient. Females had more disseminated lesions compared with more localized lesions in the males (p = 0.001). The treatment modalities in this study included chemotherapy, radiotherapy, surgery and highly active antiretroviral therapy. Overall 126 (53.4%) patients had significant improvement in quality of life at the end of 1 year follow up. Treatment related complication and mortality rates were 25.8 and 24.2% respectively. Poor ACTG stage, CD4+ count <200 cells/µl, associated co-morbid illness, disseminated disease and poor adherent to chemotherapy were the significant independent factors associated with deaths (p < 0.001). Patient's follow-up was generally poor and data on long-term survivals were not available as more than two-thirds of patients were lost to follow up.

conclusionKaposi's sarcoma is the most common malignant vascular tumor and HIV/AIDS- related cancer in our region. There is an urgent need to develop health education programmes to enhance the understanding of this disease and how it spreads, particularly among the younger generation.

Indexed as

HospitalsTertiary Health CareAdolescentAdultAgedChildChild, PreschoolFemaleFollow-Up StudiesHumansMaleMiddle AgedSarcoma, KaposiTanzaniaTreatment OutcomeYoung Adult

Identifiers

PMID26374100
PMCPMC5439227
OpenAlexW2107248017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.